Specifically, the USPTO added human serotonin receptors 5HT2A and 5HT2C to the covered molecular targets, broadening the panel's use to a wider range of neuropsychiatric targets and conditions with an underlying autoimmune origin.
Research has increasingly pointed to a relationship between infection-triggered inflammatory attacks on the brain and neuropsychiatric conditions.
Results of the Cunningham Panel assist physicians in determining the likelihood that a patient's neuropsychiatric symptoms are due to an infection-triggered autoimmune response, rather than a primary psychiatric disorder.
Moleculera Labs is a privately-held autoimmune neurobiology company whose objective is to discover and deliver advanced testing services for children and adults suffering from treatable autoimmune central nervous system disorders.
The company's initial offering is the Cunningham Panel, a set of tests aimed at assisting clinicians in the diagnosis of PANDAS and PANS, conditions associated with motor tics, obsessive compulsive disorder, and sometimes autism spectrum disorders, that researchers believe to be caused by an autoimmune response triggered by common infections.
Moleculera Labs is a technology spin-out from the University of Oklahoma and operates a full CLIA (Clinical Laboratory Improvement Amendment) and COLA (Commission on Laboratory Accreditation) certified clinical laboratory in Oklahoma City where it performs the Cunningham Panel for physicians and clinicians throughout the United States and globally.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial
Biosenic finalises agreement with Phebra for oral arsenic troxide development
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Allorion Therapeutics signs exclusive option and global license agreement with AstraZeneca